Vaccine Manufacturers

Assessing the Safety of mRNA COVID-19 Vaccination in the Immunocompromised

In a research article published yesterday in Frontiers in Oncology, COVID-19 vaccine (Pfizer and Moderna) safety was evaluated in a population of 566 immunocompromised patients including those with hematological malignancies (131), solid tumors (191), immune-rheumatological diseases (86), and neurological disease (158) including multiple sclerosis and generalized myasthenia.

Read More »

FDA Updates Recommendation Around AstraZeneca’s Evusheld

The FDA has revised its emergency use authorization for AstraZeneca’s Evusheld, a monoclonal antibody treatment for COVID-19. Due to emerging data, it has been observed that the original 150mg dose of each monoclonal antibody may be less likely to prevent infection than originally indicated. Thus, the FDA has authorized a double dose of each antibody for immunocompromised patients.

Read More »

COVID-19 Vaccine Outcomes in Dermatomyositis Patients

A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.

Read More »

Antibody Levels in Immunocompromised Patients after Second Dose of mRNA Vaccine

Researchers at Johns Hopkins tested antibody levels in patients at 1, 3, and 6 months after the second dose of an mRNA vaccine. Overall, 96% of patients had positive antibody titers 6 months after the second dose of an mRNA vaccine. Antibody responses decreased from 1 to 6 months, but remained above the threshold for “predicted neutralizing capacity” in the majority of patients.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.